

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-12 (cancelled)

Claim 13 (currently amended) A staphylokinase derivative ~~having essentially the comprising an~~ amino acid sequence ~~as depicted in figure 3 (which differs from SEQ ID NO: 10) in which one or more encircled or boxed amino acids have been replaced by another amino acid thus reducing the absorption of SakSTAR-specific antibodies from plasma of patients treated with staphylokinase and further incorporating one or more polyethylene glycol groups~~ due to the modification of the sequence with up to four amino acid substitutions consonant with the coding regions of sakOC or sak42D, further due to substitution of one or more amino acids therein with cysteine and further incorporating at least one polyethylene glycol group, thus reducing the clearance from plasma in patients and imparting a fibrinolytic or fibrinogenolytic property to the staphylokinase derivative.

Claim 14 (currently amended) The staphylokinase derivative of claim 13 in which ~~one polyethylene glycol group is coupled in position 102 thereon~~ cysteine is substituted at K102 and has a polyethylene glycol group coupled thereto.

Claim 15 (currently amended) The staphylokinase derivative of claim 13 in which the staphylokinase specific activity of the staphylokinase derivative is at least 50 percent that of wild type staphylokinase.

Claim 16 (currently amended) Staphylokinase derivatives SakSTAR(K35X, G36X, E65X, K74X, E80X, D82X, K102X, E108X, K109X, K121X, K130X, K135X, K136X, +137X) having essentially the amino acid sequence as depicted in Figure 1 (SEQ ID NO: 10) in which the amino acids Lys in position 35, Gly in position 36, Glu in position 65, Lys in position 74, Glu in position 80, Asp in position 82, Lys in position 102, Glu in position

Application No. 09/728,670  
Paper dated August 26, 2003  
In reply to USPTO Correspondence of March 26, 2003  
Attorney Docket No. 0702-001525

108, Lys in position 109, Lys in position 121, Lys in position 130, Lys in position 135 and/or Lys in position 136 have been replaced with other amino acids and/or in which one amino acid has been added at the COOH-terminus, thus altering the immunogenicity after administration in patients, and further incorporating at least one polyethylene glycol group.

Claim 17 (currently amended) Staphylokinase derivatives ~~listed in Tables 1, 2, 3, 4, 5, 6, 7 and 8,~~ having essentially the amino acid sequence depicted in figure 3 (SEQ ID NO: 10) in which the boxed or encircled amino acids have been replaced by other amino acids thus reducing the absorption of SakSTAR-specific antibodies from plasma of patients treated with staphylokinase, without reducing the specific activity, the derivative further incorporating at least one polyethylene glycol group.

Claim 18 (cancelled)

Claim 19 (cancelled)

Claim 20 (previously presented) Pharmaceutical composition comprising at least one of the staphylokinase derivatives as claimed in claim 13 together with a suitable excipient.

Claim 21 (previously presented) Pharmaceutical composition as claimed in claim 20 for treating arterial thrombosis.